Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2017 Summary Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Tyrosine-protein phosphatase non-receptor type 1 also known as protein-tyrosine phosphatase 1B (PTP1B) is an enzyme encoded by the PTPN1 gene. It acts as a regulator of endoplasmic reticulum unfolded protein response. It plays an important role in CKII- and p60c-src-induced signal transduction cascades. It regulates the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. It mediates dephosphorylation of EIF2AK3/PERK, inactivating the protein kinase activity of EIF2AK3/PERK. It regulates the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET. Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) pipeline Target constitutes close to 15 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Undisclosed which include indications Type 2 Diabetes, Obesity, Diabetes, Breast Cancer, Metastatic Breast Cancer and Rett Syndrome. The latest report Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - The report reviews Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Overview 7 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Companies Involved in Therapeutics Development 20 Aurigene Discovery Technologies Ltd 20 Ionis Pharmaceuticals Inc 20 Warp Drive Bio Inc 20 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Drug Profiles 22 Antisense Oligonucleotide to Inhibit PTP1B for Type 2 Diabetes - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Antisense Oligonucleotide to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 AU-2439 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 CPT-157633 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 DPM-1001 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 IONISPTP-1BRx - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 KQ-791 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 S-009629 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Inhibit PTP1B for Diabetes - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Inhibit PTP1B for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecules to Inhibit PTP1b for Oncology - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecules to Inhibit PTPB1 for Diabetes - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 trodusquemine - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Dormant Products 38 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Discontinued Products 40 Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Product Development Milestones 41 Featured News & Press Releases 41 Feb 03, 2015: Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes 41 May 27, 2014: DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer 42 Jul 10, 2013: Local foundation raises $15,000 for breast cancer research at Cold Spring Harbor Laboratory 42 Dec 07, 2012: Isis Pharma Reports Positive Phase I Results Of Metabolic Disorders Drug ISIS-PTP1BRx 43 Sep 29, 2011: Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 44 Jul 21, 2011: Isis Initiates Phase I Study Of ISIS-PTP1BRx To Treat Type 2 Diabetes 45 Oct 21, 2009: Isis Pharmaceuticals Reports Positive Phase 2 Data For ISIS 113715 In Patients With Type 2 Diabetes 46 Feb 10, 2009: Genaera Presents Preliminary Phase 1b Data For Trodusquemine (MSI-1436) 47 Jan 22, 2009: Genaera Presents Promising Preclinical Data For Trodusquemine (MSI-1436) At Keystone Symposia 48 Dec 01, 2008: Genaera Begins Phase 1b Trial Of Trodusquemine (MSI-1436) In Overweight And Obese Type 2 Diabetics 48 Oct 06, 2008: Genaera Corporation Reports Phase 1 Data For Trodusquemine (MSI-1436) At The North American Association For The Study Of Obesity Annual Meeting 49 Jul 25, 2008: Genaera Releases Phase 1 Data And New Preclinical Data On The CNS Function Of Trodusquemine (MSI-1436) At CBI Obesity Summit 50 Jul 14, 2008: Genaera Corporation Presents Data On Mechanism Of Inhibition Of PTP-1B For Trodusquemine (MSI-1436) At Federation Of American Societies For Experimental Biology (FASEB) Meeting 50 Jun 09, 2008: Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At American Diabetes Association 51 Mar 28, 2008: Genaera Corporation Announces MSI-1436 Data Presented At Society Of Neuroscience Meeting 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Number of Products under Investigation by Universities/Institutes, H2 2017 13 Products under Investigation by Universities/Institutes, H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 20 Pipeline by Ionis Pharmaceuticals Inc, H2 2017 20 Pipeline by Warp Drive Bio Inc, H2 2017 21 Dormant Products, H2 2017 38 Dormant Products, H2 2017 (Contd..1), H2 2017 39 Discontinued Products, H2 2017 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
